We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Real Estate 2.75%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
151
Labcorp
LH
$25.9B
$2.12M 0.08%
+14,201
New +$2.16M
WAT icon
152
Waters Corp
WAT
$37.3B
$2.1M 0.08%
+10,800
New +$2.09M
IMMU
153
DELISTED
Immunomedics Inc
IMMU
$2.03M 0.07%
+97,370
New +$2.31M
HR
154
DELISTED
Healthcare Realty Trust Incorporated
HR
$1.99M 0.07%
68,000
– –
NTLA icon
155
Intellia Therapeutics
NTLA
$1.55B
$1.97M 0.07%
68,671
-98,710
-59% -$2.87M
ACAD icon
156
Acadia Pharmaceuticals
ACAD
$4.55B
$1.95M 0.07%
93,689
– –
RVNC
157
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.94M 0.07%
77,919
– –
SPPI
158
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1.93M 0.07%
+114,670
New +$2.48M
CBAY
159
DELISTED
Cymabay Therapeutics
CBAY
$1.88M 0.07%
169,962
– –
INOV
160
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
$1.77M 0.06%
+176,163
New +$1.92M
ACHN
161
DELISTED
Achillion Pharmaceuticals
ACHN
$1.71M 0.06%
464,761
-151,239
-25% -$451K
TFX icon
162
Teleflex
TFX
$5.86B
$1.7M 0.06%
6,379
– –
ABMD
163
DELISTED
Abiomed Inc
ABMD
$1.69M 0.06%
+3,750
New +$1.48M
SNDX icon
164
Syndax Pharmaceuticals
SNDX
$1.73B
$1.62M 0.06%
200,000
– –
IMGN
165
DELISTED
Immunogen Inc
IMGN
$1.59M 0.06%
+168,190
New +$1.62M
MNK
166
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$1.57M 0.06%
53,600
-8,300
-13% -$234K
BOLD
167
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.53M 0.06%
+38,740
New +$1.44M
PHG icon
168
Philips
PHG
$25.8B
$1.51M 0.05%
+42,643
New +$1.46M
MDGL icon
169
Madrigal Pharmaceuticals
MDGL
$11.4B
$1.43M 0.05%
+6,670
New +$1.67M
ARQL
170
DELISTED
Arqule Inc
ARQL
$1.42M 0.05%
+250,000
New +$1.42M
NUVA
171
DELISTED
NuVasive, Inc.
NUVA
$1.39M 0.05%
19,580
– –
ACIU icon
172
AC Immune
ACIU
$241M
$1.38M 0.05%
171,813
– –
QURE icon
173
uniQure
QURE
$2.93B
$1.37M 0.05%
37,741
– –
CNCE
174
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.35M 0.05%
+90,724
New +$1.43M
HR icon
175
Healthcare Realty
HR
$7.46B
$1.23M 0.04%
46,000
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.